Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 5 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 7 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (moderate certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib may leads to higher progression‐free survival(absolute effect size estimates based on… compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 11 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
1 finding from 1 review
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 10 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
1 finding from 1 review
Intervention not reported
Progression‐free survival (PFS) ‐ Network (subnet 1) included 27 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention probably leads to lower progression‐free survival (PFS) ‐ Network (subnet 1) included 27… (moderate certainty).
1 finding from 1 review
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib probably leads to higher progression‐free survival (absolute effect size estimates based on… compared with pazopanib (targeted agent versus targeted agent) (moderate certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sunitinib probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
It is very uncertain whether sunitinib changes progression‐free survival (absolute effect size estimates based on… compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (very low certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus may leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent versus classic immunotherapy) (low certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
It is very uncertain whether sunitinib changes progression‐free survival (absolute effect size estimates based on… compared with atezolizumab (targeted therapy versus immunotherapy) (very low certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Bevacizumab + IFN probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (moderate certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus + IFN‐α may leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus + bevacizumab showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether everolimus + bevacizumab changes progression‐free survival (absolute effect size estimates based on… compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (very low certainty).
1 finding from 1 review